• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.

作者信息

Saburi Masuho, Ogata Masao, Soga Yasuhiro, Kondo Yoshiyuki, Kurimoto Ryo, Itani Kazuhito, Kohno Kazuhiro, Uchida Hiroki, Nakayama Toshiyuki

机构信息

Department of Hematology, Oita Kouseiren Tsurumi Hospital, Oita, Japan.

Department of Hematology, Oita University Hospital, Oita, Japan.

出版信息

J Clin Exp Hematop. 2020;60(1):17-20. doi: 10.3960/jslrt.19031.

DOI:10.3960/jslrt.19031
PMID:32224561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7187674/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/0c8ee2263d4f/jslrt-60-17-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/a0752a4e9a7b/jslrt-60-17-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/6820b333251a/jslrt-60-17-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/6a34c694d104/jslrt-60-17-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/0c8ee2263d4f/jslrt-60-17-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/a0752a4e9a7b/jslrt-60-17-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/6820b333251a/jslrt-60-17-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/6a34c694d104/jslrt-60-17-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c961/7187674/0c8ee2263d4f/jslrt-60-17-g004.jpg

相似文献

1
Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.达雷妥尤单抗和卡非佐米对新诊断的间变性多发性骨髓瘤疗效不佳。
J Clin Exp Hematop. 2020;60(1):17-20. doi: 10.3960/jslrt.19031.
2
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.在复发或难治性多发性骨髓瘤患者中，用卡非佐米治疗前后使用达雷妥尤单抗的治疗结果。
Hematol Oncol. 2021 Oct;39(4):521-528. doi: 10.1002/hon.2906. Epub 2021 Aug 2.
3
Modern treatments and future directions for newly diagnosed multiple myeloma patients.初诊多发性骨髓瘤患者的现代治疗方法和未来方向。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101151. doi: 10.1016/j.beha.2020.101151. Epub 2020 Jan 23.
4
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.达雷妥尤单抗在伴有髓外病变的多发性骨髓瘤中的疗效有限。
Leukemia. 2022 Jan;36(1):288-291. doi: 10.1038/s41375-021-01343-w. Epub 2021 Jul 10.
5
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.高危冒烟型骨髓瘤与多发性骨髓瘤的早期检测：当前模型、治疗目标及临床意义。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101152. doi: 10.1016/j.beha.2020.101152. Epub 2020 Jan 25.
6
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.卡非佐米、地塞米松和达雷妥尤单抗治疗复发或难治性多发性骨髓瘤：III期研究CANDOR按既往治疗线数的结果
Br J Haematol. 2021 Aug;194(4):784-788. doi: 10.1111/bjh.17541. Epub 2021 May 28.
7
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.新诊断和复发/难治性多发性骨髓瘤患者管理和治疗的新进展。
Expert Opin Pharmacother. 2013 Aug;14(12):1569-73. doi: 10.1517/14656566.2013.805746. Epub 2013 May 31.
8
American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.2014年美国血液学会年会：多发性骨髓瘤研究亮点
Expert Rev Hematol. 2015 Jun;8(3):273-5. doi: 10.1586/17474086.2015.1029449. Epub 2015 Mar 24.
9
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.卡非佐米用于新诊断的不适合移植的多发性骨髓瘤的维持治疗。
Leukemia. 2022 Mar;36(3):881-884. doi: 10.1038/s41375-021-01415-x. Epub 2021 Oct 14.
10
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.卡非佐米、地塞米松和达雷妥尤单抗与卡非佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（CANDOR）：一项随机、多中心、开放性、3 期研究的结果。
Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.

引用本文的文献

1
Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma.67例间变性多发性骨髓瘤患者的临床特征、治疗反应及预后分析。
World J Surg Oncol. 2025 May 31;23(1):210. doi: 10.1186/s12957-025-03851-w.
2
Anaplastic Multiple Myeloma: Case Series and Literature Review.间变性多发性骨髓瘤：病例系列与文献综述
Asploro J Biomed Clin Case Rep. 2022 Jan-Apr;5(1):1-11. doi: 10.36502/2022/asjbccr.6255. Epub 2022 Jan 15.
3
Anaplastic multiple myeloma with MYC rearrangement.伴有MYC重排的间变性多发性骨髓瘤

本文引用的文献

1
Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure.在难治性骨髓瘤合并肾衰竭患者中，单药达雷妥尤单抗治疗后实现透析独立
Ir J Med Sci. 2019 Aug;188(3):1079-1080. doi: 10.1007/s11845-018-1951-6. Epub 2018 Dec 19.
2
Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.达雷妥尤单抗联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤：CASTOR 更新分析。
Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.
3
Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Leuk Res Rep. 2021 Dec 27;17:100288. doi: 10.1016/j.lrr.2021.100288. eCollection 2022.
4
Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.来那度胺、环磷酰胺和地塞米松治疗间变性多发性骨髓瘤取得成功结果。
Ann Hematol. 2021 Dec;100(12):3039-3040. doi: 10.1007/s00277-020-04244-7. Epub 2020 Sep 2.
达雷妥尤单抗联合来那度胺和地塞米松 vs. 来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤：POLLUX 更新分析。
Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.
4
CD38-Negative Myeloma with Anaplastic Morphology at Presentation: A Case Report.初诊时具有间变形态的CD38阴性骨髓瘤：一例报告
Indian J Hematol Blood Transfus. 2018 Apr;34(2):362-364. doi: 10.1007/s12288-017-0880-2. Epub 2017 Oct 10.
5
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.达雷妥尤单抗在多发性骨髓瘤继发的透析依赖型肾衰竭中的安全性和有效性。
Haematologica. 2018 Jun;103(6):e277-e278. doi: 10.3324/haematol.2018.191122. Epub 2018 Apr 5.
6
Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission.间变性多发性骨髓瘤：传统化疗实现长期缓解的可能局限性。
J Clin Exp Hematop. 2018;58(1):39-42. doi: 10.3960/jslrt.17035.
7
Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma.1例继发性浆细胞白血病患者的骨髓瘤细胞在7天内形态转变为多叶核浆细胞，最终转变为间变性骨髓瘤。
Case Rep Hematol. 2017;2017:5758368. doi: 10.1155/2017/5758368. Epub 2017 Dec 21.
8
Pleomorphic Multinucleated Plasma Cells Simulating Megakaryocytes in an Anaplastic Variant of Myeloma.在骨髓瘤的间变性变体中模拟巨核细胞的多形多核浆细胞。
Turk J Haematol. 2018 May 25;35(2):150-151. doi: 10.4274/tjh.2017.0329. Epub 2018 Feb 6.
9
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.卡非佐米在复发多发性骨髓瘤和终末期肾病（ESRD）患者中的药代动力学及安全性：一项开放标签、单臂、I期研究。
Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076. doi: 10.1007/s00280-017-3287-8. Epub 2017 Apr 19.
10
Plasma cell myeloma with anaplastic transformation.伴有间变性转化的浆细胞骨髓瘤
Blood. 2016 Oct 20;128(16):2106. doi: 10.1182/blood-2016-08-731844.